PTPN11 and lung cancer: Herein, we have developed three new murine KRASG12C-dependent lung cancer cell lines and tested their sensitivity to a KRASG12C inhibitor as a monotherapy and in combination with a SHP2 inhibitor in vitro as well as in vivo using an orthotopic model of lung tumor growth.